PDF(Pubmed)
Abstract：
The relationship between blood group and rebleeding in acute lower gastrointestinal bleeding (ALGIB) remains unclear. This study aimed to investigate the association between blood group O and clinical outcomes in patients with ALGIB. The study included 2336 patients with ALGIB whose bleeding source was identified during initial endoscopy (from the CODE BLUE-J Study). The assessed outcomes encompassed rebleeding and other clinical parameters. The rebleeding rates within 30 days in patients with blood group O and those without blood group O were 17.9% and 14.9%, respectively. Similarly, the rates within 1 year were 21.9% for patients with blood group O and 18.2% for those without blood group O. In a multivariate analysis using age, sex, vital signs at presentation, blood test findings, comorbidities, antithrombotic medication, active bleeding, and type of endoscopic treatment as covariates, patients with blood group O exhibited significantly higher risks for rebleeding within 30 days (odds ratio [OR] 1.31; 95% confidence interval [CI] 1.04-1.65; P = 0.024) and 1 year (OR 1.29; 95% CI 1.04-1.61; P = 0.020) compared to those without blood group O. However, the thrombosis and mortality rates did not differ significantly between blood group O and non-O patients. In patients with ALGIB, blood group O has been identified as an independent risk factor for both short- and long-term rebleeding.
摘要：
急性下消化道出血（ALGIB）的血型与再出血之间的关系尚不清楚。本研究旨在探讨O型血与ALGIB患者临床结局之间的关系。该研究纳入了2336例ALGIB患者，这些患者在初次内窥镜检查中发现了出血源（来自CODEBLUE-J研究）。评估结果包括再出血和其他临床参数。O型血和非O型血患者30天内再出血率分别为17.9%和14.9%,分别。同样，血型为O的患者1年内的比率为21.9%，非血型为O的患者为18.2%。在使用年龄的多变量分析中，性别,演示时的生命体征，验血结果,合并症,抗血栓药物,活动性出血,和内镜治疗的类型为协变量，O型血患者在30天内（比值比[OR]1.31;95%置信区间[CI]1.04-1.65;P=0.024）和1年内（OR1.29;95%CI1.04-1.61;P=0.020）表现出明显较高的再出血风险。O血型和非O血型患者的血栓形成和死亡率无显著差异.在ALGIB患者中，O型血已被确定为短期和长期再出血的独立危险因素.
